Which antidepressants have demonstrated superior efficacy? A review of the evidence.

abstract：:We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia. Extensive databases searches on short-term, placebo-controlled, randomized studies of AOM and PP were performed. Indirect treatment comparisons were performed between...

journal_title：International clinical psychopharmacology

authors： Pae CU,Wang SM,Han C,Bahk WM,Lee SJ,Patkar AA,Masand PS,Serretti A,Emsley R

更新日期：2017-09-01 00:00:00

abstract：:Obsessive-compulsive disorder (OCD) has emerged as a common but frequently hidden psychiatric disorder which inflicts an intolerable burden on sufferers and demands effective management. For many years, however, OCD was considered treatment resistant and it is only in the past 15 years that effective therapy has becom...

journal_title：International clinical psychopharmacology

authors： Fineberg N

更新日期：1996-12-01 00:00:00

abstract：:Sertindole is a novel atypical antipsychotic, which has shown efficacy in the treatment of positive and negative symptoms of schizophrenia in phase II and III studies. Furthermore, these studies have demonstrated tolerability and a favourable side-effect profile. In contrast to classical antipsychotics, sertindole was...

journal_title：International clinical psychopharmacology

authors： Pezawas L,Quiner S,Moertl D,Tauscher J,Barnas C,Küfferle B,Wolf R,Kasper S

更新日期：2000-07-01 00:00:00

abstract：:The side effects of antipsychotic drugs have always been a major concern for clinicians and the appreciation of their importance in the treatment of schizophrenia has increased steadily over the years. Epidemiological studies as well as trials of the prevention and treatment of antipsychotic side effects are the conse...

journal_title：International clinical psychopharmacology

authors： Whitworth AB,Fleischhacker WW

更新日期：1995-01-01 00:00:00

abstract：:Social phobia and avoidant personality disorder were new diagnoses in the third version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) and were considerably changed in the revised third version (DSM-III-R). A high rate of comorbidity between these disorders was observed, which can be explained ...

journal_title：International clinical psychopharmacology

authors： Dahl AA

更新日期：1996-06-01 00:00:00

abstract：:Fluvoxamine, a selective serotonin reuptake inhibitor, was investigated in a 6-week double-blind study among severely ill inpatients with DSM-III major depression. All but 1 patient also fulfilled criteria for melancholia. Following a 3-day placebo wash-out patients were randomly assigned to fluvoxamine, imipramine or...

journal_title：International clinical psychopharmacology

authors： Feighner JP,Boyer WF,Meredith CH,Hendrickson GG

更新日期：1989-07-01 00:00:00

abstract：:There is uncertainty with regard to the appropriate use of metformin for the prevention and management of second-generation antipsychotic-induced weight gain and metabolic abnormalities. We aim to systematically review the primary literature and to provide recommendations with regard to the use of metformin in psychia...

journal_title：International clinical psychopharmacology

authors： Newall H,Myles N,Ward PB,Samaras K,Shiers D,Curtis J

更新日期：2012-03-01 00:00:00

abstract：:The sedative properties of two doses (50 and 150 mg) of a benzodiazepine partial agonist, PK 8165 (pipequaline), were compared to diazepam 10 mg and placebo in 12 normal volunteers. The assessment, performed before drug intake and 2 and 5 hours after drug intake, included a battery of visual analogue scales and standa...

journal_title：International clinical psychopharmacology

authors： von Frenckell R,Ansseau M,Bonnet D

更新日期：1986-01-01 00:00:00

abstract：:Premenstrual dysphoria (PMD) is a severe form of premenstrual syndrome, afflicting approximately 5% of all women of fertile age. The cardinal symptoms are irritability and anger. In addition, sadness, tension and carbohydrate craving are common complaints. The symptoms surface regularly between ovulation and menstruat...

journal_title：International clinical psychopharmacology

authors： Eriksson E

更新日期：1999-05-01 00:00:00

abstract：:A new selective MAO-A-inhibitor (noclobemide) was used in a double-blind comparative study of 23 patients with severe unipolar or bipolar depressive disorder. Two different doses of medication were given for 4 weeks. Effectiveness was measured by improvements in the Hamilton Rating Scale for Depression, a self-rating ...

journal_title：International clinical psychopharmacology

authors： Lensch K,Fuchs G,Böning J,Milech U

更新日期：1987-04-01 00:00:00

abstract：:"Agitation" is a term that is used to describe a wide range of dysfunctional behaviours in geriatric populations. The term is so widely used that in many cases it loses clinical meaning and therefore a more restricted use of the term is suggested. When patients with agitation are identified it is important to look for...

journal_title：International clinical psychopharmacology

authors： Ancill RJ,Carlyle WW,Liang RA,Holliday SG

更新日期：1991-01-01 00:00:00

abstract：:Eighteen patients with rapid cycling bipolar affective disorder were recruited for an open trial of carbamazepine. Of these patients all but 2 had been resistant to lithium prophylaxis. Twelve of the patients were able to complete at least 6 months on carbamazepine. Of these 12 patients, 2 had a complete remission of ...

journal_title：International clinical psychopharmacology

authors： Joyce PR

更新日期：1988-04-01 00:00:00

abstract：:Characteristic response patterns are described for two antidepressant drugs and placebo in post-traumatic stress disorder. Early onset and steady improvement occurred on a global rating scale for both drugs and placebo in those who ultimately met responder criteria at the end of treatment. In certain cases, the magnit...

journal_title：International clinical psychopharmacology

authors： Davidson JR,Malik ML,Sutherland SN

更新日期：1997-11-01 00:00:00

abstract：:In recent years the efficacy of new antipsychotics has been investigated through a number of randomized controlled trials. This paper considers some methodological flaws that affect these studies and proposes possible solutions. The final goal is the implementation of a new generation of trials with the aim of demonst...

journal_title：International clinical psychopharmacology

authors： Barbui C,Garattini S

更新日期：1999-03-01 00:00:00

abstract：:Musical hallucinations (MHs), characterized by the hearing of tunes, melodies, or songs, is a relatively under-recognized phenomenon among elderly individuals with hearing impairment. In some patients, MHs represent a complex psychopathological phenomenon, hallucinatory in content and obsessive-compulsive (OC) in form...

journal_title：International clinical psychopharmacology

authors： Bergman J,Pashinian A,Weizman A,Poyurovsky M

更新日期：2014-09-01 00:00:00

abstract：:Sixteen young male volunteers received single doses of moclobemide 200 mg, moclobemide 400 mg, amitriptyline 50 mg and placebo in a double-blind crossover study. Subjects then completed a test battery which is sensitive to the effects of psychoactive drugs at 1, 2, and 4 h post-dose. The test battery included tasks of...

journal_title：International clinical psychopharmacology

authors： Fairweather DB,Kerr JS,Hindmarch I

更新日期：1993-04-01 00:00:00

abstract：:The effects of moclobemide, 450 mg/day, on sleep were investigated in 12 patients with major depression. The study was carried out over six weeks, divided into three periods: (1) treatment for one week with placebo and measurement to obtain baseline values; (2) treatment with moclobemide for four weeks; and (3) one we...

journal_title：International clinical psychopharmacology

authors： Minot R,Luthringer R,Macher JP

更新日期：1993-01-01 00:00:00

abstract：:Thirty healthy subjects 12 males and 18 females were given the acetylcholinesterase inhibitor pyridostigmine (120 mg) orally. The growth hormone (GH) response was measured as the maximum GH level post-pyridostigmine relative to baseline. Twenty-six subjects increased their GH level in response to pyridostigmine. Respo...

journal_title：International clinical psychopharmacology

authors： Lucey JV,O'Keane V,O'Flynn K,Clare AW,Dinan TG

更新日期：1991-07-01 00:00:00

abstract：:The effect of the antipsychotic drug trifluoperazine (TFP) on the in-vitro growth of 50 clinical isolates of Mycobacterium tuberculosis was tested. Of these isolates, 29 were susceptible to all five of the antitubercular drugs isoniazid, rifampicin, streptomycin, ethambutol and pyrazinamide, and 21 were resistant to o...

journal_title：International clinical psychopharmacology

authors： Gadre DV,Talwar V,Gupta HC,Murthy PS

更新日期：1998-05-01 00:00:00

abstract：:This study evaluated the efficacy of pregabalin augmentation of antidepressant treatment in patients with posttraumatic stress disorder (PTSD). Nine patients meeting Diagnostic and Statistical Manual, fourth edition criteria for PTSD who were on stable doses of antidepressants were treated open label with flexibly dos...

journal_title：International clinical psychopharmacology

authors： Pae CU,Marks DM,Han C,Masand PS,Patkar AA

更新日期：2009-01-01 00:00:00

abstract：:Three placebo-controlled double-blind and crossover trials were carried out to analyze the effects of oral yohimbine (YOH) 0.8 mg/kg on mood and performance in 16 healthy students. Subjective assessments (visual analogue scales, side-effects on questionnaire) and objective measurements (digit symbols, flicker fusion, ...

journal_title：International clinical psychopharmacology

authors： Mattila M,Seppala T,Mattila MJ

更新日期：1988-07-01 00:00:00

abstract：:The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia. Symptoms indicating mania were assessed by the Positive and Negative Syndrome Scale (PANSS) excitement and grandiosi...

journal_title：International clinical psychopharmacology

authors： Peuskens J,Van Baelen B,De Smedt C,Lemmens P

更新日期：2000-11-01 00:00:00

abstract：:The utility of milnacipran in the treatment of major depression has been the subject of an extensive clinical development programme. Comparative studies with tricyclic antidepressant drugs have demonstrated equivalent efficacy, with improved tolerability, in particular with respect to autonomic effects. In comparison ...

journal_title：International clinical psychopharmacology

authors： Bisserbe JC

更新日期：2002-06-01 00:00:00

abstract：:Long-term treatment with benzodiazepines (BZD) should be avoided in dementia patients because of an increased risk of adverse events. We evaluated how continuously dementia patients were prescribed BZD over 12 months. For this observational study, we used claims data from a large German public sickness fund for 2014 a...

journal_title：International clinical psychopharmacology

authors： Hessmann P,Jan Zeidler,Neubauer S,Abdel-Hamid M,Stahmeyer J,Eberhard S,Wolff-Menzler C,Wiltfang J,Kis B

更新日期：2018-09-01 00:00:00

abstract：:In an earlier study, we found a similar frequency of individuals with an abnormal correlation between serum leptin levels and body mass index (BMI) (outliers above or below the 95% confidence interval in the regression line) during treatment with antipsychotic drugs (n=301), other psychotropic drugs (n=65), and drug-f...

journal_title：International clinical psychopharmacology

authors： Marquina D,Peña R,Fernández E,Baptista T

更新日期：2011-05-01 00:00:00

abstract：:A number of compounds having an effect on serotonergic transmission have been shown to have a beneficial therapeutic action in patients with bulimia nervosa. Many previous studies, however, have suffered from methodological shortcomings, in particular small population sizes. This article reviews present data which sug...

journal_title：International clinical psychopharmacology

authors： Wood A

更新日期：1993-01-01 00:00:00

abstract：:The effects of an abrupt interruption of agomelatine, a new melatonergic/serotonergic antidepressant, were explored in a double-blind, placebo-controlled study. Paroxetine was used as active control. After 12 weeks of double-blind treatment with agomelatine 25 mg/day or paroxetine 20 mg/day, sustained remitted depress...

journal_title：International clinical psychopharmacology

authors： Montgomery SA,Kennedy SH,Burrows GD,Lejoyeux M,Hindmarch I

更新日期：2004-09-01 00:00:00

abstract：:Depressive symptoms are associated with poor outcomes, increased risk of relapse, and high suicide rates in patients with schizophrenia and schizoaffective disorder. This randomized, open-label, parallel-group, flexible-dose study (NCT00640562) assessed the efficacy of quetiapine extended release (XR) versus risperido...

journal_title：International clinical psychopharmacology

authors： Di Fiorino M,Montagnani G,Trespi G,Kasper S

更新日期：2014-05-01 00:00:00

abstract：:The pattern of brain metabolic changes produced by olanzapine has yet to be described, despite the theoretical and clinical interest of this new antipsychotic. We studied a group of 17 schizophrenic patients who underwent two fluoro-deoxyglucose-positron emission tomography (FDG-PET) studies under two different condit...

journal_title：International clinical psychopharmacology

authors： Molina V,Gispert JD,Reig S,Pascau J,Martínez R,Sanz J,Palomo T,Desco M

更新日期：2005-01-01 00:00:00

abstract：:Serotonin reuptake inhibitors (SSRI), such as venalafaxine and paroxetine, are used in the treatment of generalized anxiety disorder (GAD). Patients with GAD frequently have comorbid psychiatric disorders, such as depression. SSRIs are effective in the treatment of a variety of anxiety disorders and depression. Citalo...

journal_title：International clinical psychopharmacology

authors： Varia I,Rauscher F

更新日期：2002-05-01 00:00:00